On 11 March 2020, the World Health Organisation (WHO) declared COVID-19 a pandemic. Early epidemiological estimates show that COVID-19 is highly transmissible, infecting populations across the globe in a short amount of time. WHO has recommended widespread clinical testing in order to contain COVID-19. However, mass testing in emergency department (ED) settings may result in crowded EDs and increase transmission risk for healthcare staff and other ED patients. Drive-through COVID-19 testing sites are an effective solution to quickly collect samples from suspected cases with minimal risk to healthcare personnel and other patients. Nevertheless, there are many logistical and operational challenges, such as shortages of testing kits, limited numbers of healthcare staff and long delays for collecting samples. Solving these problems requires an understanding of disease dynamics and epidemiology, as well as the logistics of mass distribution. In this position paper, we provide a conceptual framework for addressing these challenges, as well as some insights from prior literature and experience on developing decision support tools for public health departments.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476486 | PMC |
| http://dx.doi.org/10.1080/20476965.2020.1758000 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunologic assessment of the impact of SARS-CoV-2 vaccine booster doses on humoral immunity: a cross-sectional study in morocco.
BMC Infect Dis
December 2024
Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc, 1 Place Louis Pasteur, Casablanca, 20360, Morocco.
To assess the impact of the SARS-CoV-2 booster dose on the immune response against COVID-19, we conducted a cross-sectional study in the Casablanca-Settat region of Morocco. The study included 2,802 participants from 16 provinces, all of whom had received three doses of a SARS-CoV-2 vaccine. IgG antibodies targeting the S1 RBD subunit of the SARS-CoV-2 spike protein were quantified using the SARS-CoV-2 IgG II Quant assay and measured on the Abbott Architect i2000SR instrument.
View Article and Find Full Text PDFFour COVID-19 screening strategies for early case identification within the homeless shelter population: a cluster randomized controlled trial.
BMC Infect Dis
December 2024
Department of Medicine, McMaster University, Hamilton, ON, Canada.
Background: To compare the effectiveness of four surveillance strategies for detecting SARS-CoV-2 within the homeless shelter population in Hamilton, ON and assess participant adherence over time for each surveillance method.
Methods: This was an open-label, cluster-randomized controlled trial conducted in eleven homeless shelters in Hamilton, Ontario, from April 2020 to January 2021. All participants who consented to the study and participated in the surveillance were eligible for testing by self-swabbing.
Comparison of clinical characteristics and outcomes in candidaemia patients with and without COVID-19: a multicentre retrospective study.
BMC Infect Dis
December 2024
Department of Infectious Disease, Department of Internal Medicine, Chonnam National University Medical School, 42, Jebong Ro, Donggu, Gwangju, 61469, South Korea.
Background: Invasive fungal infections have been reported as complications with significant mortality and morbidity in patients hospitalized with COVID-19. This study aimed to evaluate the clinical characteristics and outcomes of candidaemia patients with COVID-19 and to investigate the association between COVID-19 and mortality in candidaemia patients.
Methods: This retrospective study included candidaemia patients aged 18 years or older admitted to four university-affiliated tertiary hospitals in South Korea between January 1, 2020, and December 31, 2022.
Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya.
BMC Infect Dis
December 2024
KEMRI-Wellcome Trust Research Programme, P.O. Box 230, Kilifi, Kenya.
Increased immune evasion by emerging and highly mutated SARS-CoV-2 variants is a key challenge to the control of COVID-19. The majority of these mutations mainly target the spike protein, allowing the new variants to escape the immunity previously raised by vaccination and/or infection by earlier variants of SARS-CoV-2. In this study, we investigated the neutralizing capacity of antibodies against emerging variants of interest circulating between May 2023 and October 2024 using sera from representative samples of the Kenyan population.
View Article and Find Full Text PDFCorrigendum to 'Health impacts of daily weather fluctuations: Empirical evidence from COVID-19 in U.S. counties' [J. Environ. Manag. (2021) 112662].
J Environ Manage
December 2024
Manchester Metropolitan University, UK. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!